US-based biotechnology companies Exelixis and MSD have partnered to assess the potential of combining their respective cancer ...

Merck & Co has extended its range of cancer medicines in the US after claiming FDA approval for Welireg – a drug it acquired as part of its $2.2 billion takeover of Peloton Therapeutics in 2019 ...

Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was ...

Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...

Patients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD's Welireg via the NHS, nearly a year after their counterparts in Scotland. In final draft ...

Belzutifan (Welireg, Merck Sharp & Dohme) is indicated for 'the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively. ALAMEDA ...

The companies will also evaluate zanzalintinib with WELIREG (belzutifan), Merck's oral hypoxia-inducible factor-2 alpha (HIF-2) inhibitor, in a phase 1/2 trial and two phase 3 pivotal trials for ...